Protagic Therapeutics因跌破股权并违反规则，面临被下架的风险，被纳斯达克警告。 Protagenic Therapeutics got a Nasdaq warning for falling below equity and filing rules, risking delisting.

2025年11月27日收到了Nasdaq(PTIX)通知,指出它不再符合两项上市规则:股东最低股本250万美元和及时提交定期报告。 Protagenic Therapeutics (PTIX) received a Nasdaq notice on November 27, 2025, stating it no longer complies with two listing rules: minimum stockholders’ equity of $2.5 million and timely filing of periodic reports. 这些问题源于2025年6月30日的一份报告,其中显示股本不足和提交2025年第三季度表格10-Q的延迟。 The issues stem from a June 30, 2025, report showing insufficient equity and a delay in filing its third-quarter 2025 Form 10-Q. 该公司正在最后审定逾期未交的报告,并计划要求Nasdaq小组举行听证会,以寻求中止和延长时间,以重新遵守规定。 The company is finalizing the overdue report and plans to request a hearing before a Nasdaq panel to seek a stay and additional time to regain compliance. 没有保证Nasdaq会给予救济。 There is no guarantee Nasdaq will grant relief. 在这一过程中,该股票将继续交易。 The stock will continue trading during the process. Protagenic是一家临床阶段的生物制药公司，致力于开发神经和神经精神疾病的治疗方法。 Protagenic is a clinical-stage biopharmaceutical company developing treatments for neurological and neuropsychiatric conditions.